Latest News of ABBV
Here are Friday's biggest analyst calls: Nvidia, Apple, Nike, Microsoft, Flutter, Amazon, Arm, Affirm, AbbVie & more
By CNBC |
23 hours ago
Friday's key Wall Street calls included Goldman Sachs initiating Flutter and Aecom as buys, Citi reiterating Apple as a buy, and UBS initiating Roku as neutral. Redburn Atlantic Equities reiterated Mi...
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
By Yahoo! Finance |
5 days ago
AbbVie Inc. is increasing its dividend to $1.64, exceeding industry averages. Despite high payouts, strong cash flows suggest sustainability. While dividend growth may be limited, AbbVie's stable trac...
Why AbbVie's (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment
By Yahoo! Finance |
6 days ago
AbbVie stock dropped 10% after its schizophrenia drug failed in trials. Despite investor concerns, the setback is seen as a buying opportunity. AbbVie focuses on innovative medicines, with top product...
-
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
By Yahoo! Finance | 1 week agoAbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
-
Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup
By MarketWatch | 1 week agoHealth-care stocks fell due to concerns over AbbVie and Humana. AbbVie's shares dropped by over 12% following disappointing results from its schizophrenia drug trials. Conversely, Bristol Myers' stock...
-
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
By MarketWatch | 1 week agoBristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%....
-
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
By MarketWatch | 1 week agoAbbVie's stock dropped significantly as their schizophrenia drug, emraclidine, failed to show significant improvement in two Phase 2 trials. The drug did not meet the primary endpoint of demonstrating...
-
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
By Yahoo! Finance | 1 week agoAbbVie Inc. faces a setback as its drug for schizophrenia failed in trials, causing shares to drop significantly. This news benefits Bristol Myers Squibb Co., which recently gained approval for a new ...
-
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
By Yahoo! Finance | 2 weeks agoInvestors often rely on analyst recommendations from brokerage firms to make stock decisions. However, these recommendations may not always be reliable due to potential biases. The Zacks Rank, a quant...
-
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
By Yahoo! Finance | 2 weeks agoThe pharmaceutical industry is booming, with a focus on innovative research and development. AbbVie Inc. is one of the top pharma stocks to watch. Advances in medical technology and AI are transformin...
-
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
By Yahoo! Finance | 3 weeks agoAbbVie reported quarterly earnings of $3 per share, beating estimates. The company's revenue also exceeded expectations. With a strong performance, investors await management's guidance for future gro...
-
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi
By Investor's Business Daily | 3 weeks agoAbbVie (ABBV) stock rose as it reported Q3 earnings of $3 per share on $14.46 billion in sales, beating analyst estimates. Sales of new drugs Skyrizi and Rinvoq surpassed expectations, with Skyrizi ou...
-
Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet?
By Yahoo! Finance | 3 weeks agoDavid Iben emphasized that avoiding permanent loss of capital is more crucial than volatility. Debt can be risky for a company, leading to bankruptcy or dilution of shareholders. Assessing a company's...
-
AbbVie's Bold $1.4 Billion Bet: The Alzheimer's Breakthrough Investors Have Been Waiting For
By Yahoo! Finance | 3 weeks agoAbbVie's strategic acquisition of Aliada Therapeutics for $1.4 billion is a significant move into Alzheimer's innovation. The acquisition enhances AbbVie's R&D capabilities with cutting-edge technolog...
-
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
By Yahoo! Finance | 1 month agoThe U.S. FDA has approved AbbVie's VYALEV, a continuous levodopa infusion for advanced Parkinson's disease. Studies show improved motor symptom management compared to oral medication....